We are live on
!
Find out more
AUTL
Autolus Therapeutics
AUTL
AUTL
84 hedge funds and large institutions have $184M invested in Autolus Therapeutics in 2026 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 30 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.84% less ownership
Funds ownership: 52.36% → 50.51% (-1.8%)
6% less funds holding
Funds holding: 89 → 84 (-5)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
27% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 30
33% less capital invested
Capital invested by funds: $277M → $184M (-$92.7M)
Holders
84
Holders Change
-5
Holders Change %
-5.62%
% of All Funds
1.03%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
9
Increased
22
Reduced
30
Closed
12
Calls
$643K
Puts
–
Net Calls
+$643K
Net Calls Change
+$80K
Top Buyers
| 1 |
MCO
MAK Capital One
New York
|
+$5.49M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.48M |
| 3 |
MG
Marex Group
London,
|
+$825K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$651K |
| 5 |
Millennium Management
New York
|
+$311K |
Top Sellers
| 1 |
BlackRock
New York
|
-$3.35M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.7M |
| 3 |
AC
Armistice Capital
New York
|
-$2.58M |
| 4 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$2.33M |
| 5 |
Renaissance Technologies
New York
|
-$1.22M |
